)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Xintela
Xintela (XINT) investor relations material
Xintela Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary29 May, 2026
Executive summary
Achieved primary objective in Phase I/IIa clinical study of XSTEM for hard-to-heal venous leg ulcers, confirming safety and tolerability.
Expanded patent portfolio with new grants in the US (wound healing) and Japan (ARDS), strengthening commercialization prospects.
EQSTEM publication on osteoarthritis in horses received a scientific award, supporting disease-modifying claims.
Ongoing revenue from GMP collaborations and new board appointments to support strategic growth.
Financial highlights
Net sales for Q1 2026 were TSEK 443, up from TSEK 140 in Q1 2025.
Group operating loss for Q1 2026 was TSEK -11,205, compared to TSEK -10,094 in Q1 2025.
Loss before tax for Q1 2026 was TSEK -11,780, versus TSEK -10,661 year-over-year.
Cash and cash equivalents at March 31, 2026, were TSEK 9,783, up from TSEK 6,398 a year earlier.
Cash flow for Q1 2026 was TSEK -12,932, compared to TSEK -10,214 in Q1 2025.
Outlook and guidance
Strategy focuses on establishing partnerships and commercial collaborations for XSTEM in osteoarthritis and wound healing.
Evaluating early market introduction of XSTEM in select markets based on existing clinical data.
Continued efforts to secure financing and strengthen business development capabilities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Xintela
- XSTEM clinical results drive partnership interest as financial losses widen but funding is secured.XINT
Q4 202527 Feb 2026 - XSTEM's highest dose halted cartilage loss and improved bone structure in OA patients for two years.XINTInvesting in Life Science 202515 Dec 2025
- XSTEM delivered long-term efficacy in osteoarthritis, with ongoing clinical and partnership progress.XINTQ3 20254 Nov 2025
- XSTEM osteoarthritis study completed; strong warrant uptake boosts cash amid ongoing losses.XINTQ2 202529 Aug 2025
- Improved results, clinical progress, and new financing position Xintela for next-stage growth.XINTQ3 202413 Jun 2025
- Losses narrowed as Xintela advanced clinical programs and secured new development agreements.XINTQ2 202413 Jun 2025
- XSTEM's 18-month osteoarthritis results and EQSTEM's global licensing drive Xintela's Q1 progress.XINTQ1 20256 Jun 2025
- Xintela reached key clinical milestones and strengthened its finances while pursuing new partnerships.XINTQ4 20245 Jun 2025
Next Xintela earnings date
Q2 202628 Aug, 2026
Xintela
Next Xintela earnings date
Q2 202628 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage